Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Battat, Robert , Duijvestein, Marjolijn , Guizzetti, Leonardo , Choudhary, Daksh , Boland, Brigid S. , Dulai, Parambir S. , Parker, Claire E. , Nguyen, Tran M , Singh, Siddharth , Pai, Rish K. , Feagan, Brian G. , Sandborn, William J. , Guizzetti, L , Casteele, Niels Vande , Jairath, Vipul

Mayo Clinic

American Journal of Gastroenterology | January 29, 2019 | Volume: 114 | Issue: 5 | Pages: 733-745

10.14309/ajg.0000000000000111 | PMID 30694863 Get It

OBJECTIVES: Histologic remission is a potentially valuable means of assessing disease activity and treatment response in ulcerative colitis (UC). However, the efficacy of existing therapies to achieve this outcome is unclear. We performed a systematic review and meta-analysis of histologic outcomes in UC randomized controlled trials and examined the relationship between histologic and endoscopic outcomes. METHODS: MEDLINE, EMBASE, CENTRAL, and the Cochrane IBD Register were searched for randomized controlled trials of aminosalicylates, corticosteroids, immunosuppressives, biologics, and small molecules. Histologic and endoscopic remission and response data were independently extracted and pooled using binomial–normal random-effect or fixed-effect models. Pooled efficacy estimates were calculated as risk ratios (RRs) using the Mantel–Haenszel method. Univariable and multivariable random-effect meta-regression models examined factors associated with histologic remission. RESULTS: Seventy-four studies (68 induction and 7 maintenance) were identified. Topical aminosalicylate enemas [37.2%, 95% confidence interval (CI), 29.0–46.3] and suppositories (44.9%, 95% CI, 28.9–62.3) had the highest induction of histologic remission rates. Aminosalicylate enemas (RR = 4.14, 95% CI, 2.35–7.31), aminosalicylate suppositories (RR = 3.94, 95% CI, 1.26–12.32), and budesonide multimatrix (RR = 1.47, 95% CI 1.08–1.99) had higher histologic remission rates than placebo. Data were lacking for biologics and immunosuppressives. The pooled histologic remission rate for placebo in induction studies was 10.4% (95% CI, 7.1–15.2). Histologic and endoscopic remission correlated strongly ( r = 0.66; 95% CI, 0.50–0.78). In multivariate analysis of placebo-arm data, less severe clinical disease activity and corticosteroid use were associated with higher histologic remission rates. Similarly, mild clinical disease activity was associated with higher histologic remission rates when active-arm data were analyzed. CONCLUSIONS: Histologic remission rates for current UC treatments ranged from 15.0% to 44.9% according to drug class and patient population with the highest rates observed for topical aminosalicylates. Placebo remission rates were low with relatively narrow CIs. These data provide benchmarks to inform future trial design. Histologic remission is a potential treatment target in clinical practice.
Gastrointestinal: Positron emission tomography–computed tomography imaging of multifocal intestinal metastasis from primary lung cancer
Nguyen, BD, Ryan, M

Mayo Clinic

Journal of Gastroenterology and Hepatology | January 28, 2019 | Volume: 34 | Issue: 5 | Pages: 814-814

10.1111/jgh.14591 | PMID 30693593 Get It

Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis
Hellstrom, Wayne J.G. , Nguyen, Hoang Minh Tue, Alzweri, Laith , Chung, Amanda , Tapscott, Ashley, Ziegelmann, Matthew , Trost, Landon , Gelbard, Martin K. , Nguyen, Hoang Minh Tue, Virasoro, Ramón

Mayo Clinic

Journal of Urology | January 18, 2019 | Volume: 201 | Issue: 4 | Pages: 777-782

10.1097/ju.0000000000000032 | PMID 30672843 Get It

Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.
Han, Leona C., Shah, Nilay D. , Gross, Cary P. , Smaldone, Marc C., Tilburt, Jon C. , Trinh, Q.D., Karnes, R. Jeffrey , Ranasinghe, Weranja Kalana Bodhisiri, Sun, Maxine , Kim, Simon P. , Ranasinghe, Weranja , Ross, Joseph S. , Nguyen, Paul L. , Yu, James B.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16085-e16085

10.1200/jco.2014.32.15_suppl.e16085 Get It

Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series
Rowland, Kendrith M. , Atherton, Pamela J., Dakhil, Christopher, Sun, Zhifu , Tan, Angelina D., Schmidt, Lucy J., Nguyen, Phuong L., Breitkopf, Carmen Radecki , Pittelkow, Mark R. , Tindall, Donald J., Menon, Smitha, Jatoi, Aminah , Atherton, Philip J. , Tan, Angelina, Schmidt, Lucy, Tindall, Donald, Jatoi, Aminah , Sun, Zhifu , Le‐Rademacher, Jennifer , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | January 3, 2019 | Volume: 36 | Issue: 6 | Pages: 519-525

10.1177/1049909118819820 | PMID 30602311 Get It

Background: Although 50% to 90% of patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash, options for rash prevention or palliation remain limited. This issue is particularly important from a palliative care standpoint because these agents are prescribed only to patients with incurable cancer. Here, we report (1) gene expression profiling of skin biopsies from patients with an EGFR inhibitor–induced rash and (2) a randomized, placebo-controlled feasibility trial with the antiandrogen, spironolactone. Both investigations were undertaken to begin to explore the hypothesis that androgens mediate EGFR inhibitor–induced rash and that antiandrogens palliate it. Methods/Results: First, 4 skin biopsies from patients with EGFR inhibitor–induced rash (3 men and 1 woman) were subject to gene expression microarray profiling. A public data set of normal skin gene expression (Gene Expression Omnibus, GSE22998) served as a reference. Sixty percent of commonly interrogated androgen receptor genes (207 of 308 between the 2 data sets) were differentially expressed ( P < .05) in the rash samples. Second, in a 17-patient double-blinded, placebo-controlled trial with topical spironolactone applied to the face, although the primary feasibility end point was not achieved, patients in the spironolactone arm received more doses of EGFR inhibitor, and anecdotal photographic evidence suggested salutatory effects of spironolactone on rash. Conclusions: Epidermal growth factor receptor inhibitor–induced rash appears to be androgen-mediated; antiandrogen therapy merits further study for rash prevention/palliation.
Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).
Hurwitz, Herbert I. , Nguyen, Quynh Lan, Osborne, Stuart, Yau, Linda, Talbot, Jonathan, Srock, Stefanie, Lenz, Heinz‐Josef , Loupakis, Fotios , Saltz, Leonard B. , Arnold, Dirk , Grothey, Axel , Nguyen, Quynh Lan, Yau, Linda

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 726-726

10.1200/jco.2018.36.4_suppl.726 Get It

726 Background: Primary tumor location is an important prognostic factor in mCRC. Efficacy differences with EGFR antibodies by tumor location show a predictive effect (Arnold et al. Ann Oncol 2017). Two first-line (1L) pivotal bev trials showed the prognostic value of sidedness (Loupakis et al. J Natl Cancer Inst 2015). In this exploratory study, further analysis of the predictive effect of bev is presented. Methods: Data from two randomized phase III studies (NO16966 [NCT00069095], AVF2107g [NCT00109070]) of bev+CT vs CT-alone as 1L treatment for mCRC were analyzed retrospectively. Patients (pts) with sidedness information available were included; pts from NO16966 (part 1) randomized to CT only were excluded. Sidedness was identified by case report forms. Results: Sidedness was determined in 1590 pts (27% Right and 73% Left) out of 2214 pts total (Table). In the pooled analysis, PFS improved with bev+CT compared to CT only in both right-sided (HR=0.75; 95% CI 0.61, 0.93) and left-sided (HR=0.76; 95% CI 0.67, 0.86) mCRC with similar magnitude of benefit in both sides. OS also improved with bev+CT in right-sided (HR=0.82; 95% CI 0.65, 1.03) and left-sided (HR=0.85; 95% CI 0.74, 0.98) pts. Conclusions: This exploratory subgroup analysis of two pivotal studies indicates that the effect of bev is independent of tumor location in mCRC patients. Survival outcomes. Clinical trial information: NCT00069095 and NCT00109070. [Table: see text]
“Migratory” Pattern of Corticosteroid-Related Multifocal Bone Infarction on Bone Scintigraphy
Roarke, Michael A., Yang, Ming , Roarke, Michael C., Nguyen, Ba D.

Mayo Clinic

Clinical Nuclear Medicine | December 18, 2018 | Volume: 44 | Issue: 2 | Pages: 155-156

10.1097/rlu.0000000000002403 | PMID 30562189 Get It

Abstract We present serial bone scintigraphy examinations in a 38-year-old woman who presented with posterior left rib pain in the setting of adrenal insufficiency secondary to pituitary damage as a result of radiation treatment for orbital sarcoma.
Synchronous Lesions of the Right Accessory Parotid Gland and Left Main Parotid Gland
Nguyen, Ba D.

Mayo Clinic

Ear, Nose & Throat Journal | December 4, 2018 | Volume: 96 | Issue: 6 | Pages: 200-203

10.1177/014556131709600617 | PMID 28636728 Get It

GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score
Yang, Ju Dong , Addissie, Benyam D., Mara, Kristin C. , Harmsen, William S. , Dai, Jianliang , Zhang, Ning , Wongjarupong, Nicha , Ali, Hawa M. , Ali, Hamdi A. , Hassan, Fatima, Lavu, Sravanthi , Cvinar, Jessica, Giama, Nasra H., Moser, Catherine D., Miyabe, Katsuyuki , Allotey, Loretta K., Theobald, Jannick , Ward, Melissa M., Nguyen, Mindie H. , Befeler, Alex S. , Reddy, K. Rajender , Schwartz, Myron , Harnois, Denise M. , Srivastava, Sudhir , Rinaudo, Jo Ann, Feng, Ziding , Marrero, Jorge A. , Roberts, Lewis R. , Hassan, Fatima A, Cvinar, Jessica L, Theobald, J Paul, Roberts, Lewis R , Miyabe, Katsuyuki , Mara, Kristin C , Yang, Ju Dong , Algeciras‐Schimnich, Alicia , Theobald, J. Paul, Yamada, Hiroyuki , Gores, Gregory J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 21, 2018 | Volume: 28 | Issue: 3 | Pages: 531-538

10.1158/1055-9965.epi-18-0281 | PMID 30464023 Get It

Abstract Background: The GALAD score is a serum biomarker–based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison with liver ultrasound for detection of HCC. Methods: A single-center cohort of 111 HCC patients and 180 controls with cirrhosis or chronic hepatitis B and a multicenter cohort of 233 early HCC and 412 cirrhosis patients from the Early Detection Research Network (EDRN) phase II HCC Study were analyzed. Results: The area under the ROC curve (AUC) of the GALAD score for HCC detection was 0.95 [95% confidence interval (CI), 0.93–97], which was higher than the AUC of ultrasound (0.82, P &lt;0.01). At a cutoff of −0.76, the GALAD score had a sensitivity of 91% and a specificity of 85% for HCC detection. The AUC of the GALAD score for early-stage HCC detection remained high at 0.92 (95% CI, 0.88–0.96; cutoff −1.18, sensitivity 92%, specificity 79%). The AUC of the GALAD score for HCC detection was 0.88 (95% CI, 0.85–0.91) in the EDRN cohort. The combination of GALAD and ultrasound (GALADUS score) further improved the performance of the GALAD score in the single-center cohort, achieving an AUC of 0.98 (95% CI, 0.96–0.99; cutoff −0.18, sensitivity 95%, specificity 91%). Conclusions: The performance of the GALAD score was superior to ultrasound for HCC detection. The GALADUS score further enhanced the performance of the GALAD score. Impact: The GALAD score was validated in the United States.
Developmental delay and failure to thrive associated with a loss‐of‐function variant in WHSC1 (NSD2)
Boczek, Nicole J. , Lahner, Carrie A., Nguyen, Thuy‐mi , Ferber, Matthew J. , Hasadsri, Linda , Thorland, Erik C., Niu, Zhiyv , Gavrilova, Ralitza H. , Niu, Zhiyv

Mayo Clinic

American Journal of Medical Genetics Part A | October 22, 2018 | Volume: 176 | Issue: 12 | Pages: 2798-2802

10.1002/ajmg.a.40498 | PMID 30345613 Get It

Wolf‐Hirschhorn syndrome (WHS) is a microdeletion syndrome characterized by distinctive facial features consisting of “Greek warrior helmet” appearance, prenatal and postnatal growth deficiency, developmental disability, and seizures. This disorder is caused by heterozygous deletions on chromosome 4p16.3 often identified by cytogenetic techniques. Many groups have attempted to identify the critical region within this deletion to establish which genes are responsible for WHS. Herein, clinical whole exome sequencing (WES) was performed on a child with developmental delays, mild facial dysmorphisms, short stature, failure to thrive, and microcephaly, and revealed a de novo frameshift variant, c.1676_1679del (p.Arg559Tfs*38), in WHSC1 (NSD2). While WHSC1 falls within the WHS critical region, individuals with only disruption of this gene have only recently been described in the literature. Loss‐of‐function de novo variations in WHSC1 were identified in large developmental delay, autism, diagnostic, and congenital cardiac cohorts, as well as recent case reports, suggesting that de novo loss‐of‐function WHSC1 variants may be related to disease. These findings, along with our patient suggest that loss‐of‐function variation in WHSC1 may lead to a mild form of Wolf‐Hirschhorn syndrome, and also may suggest that the developmental delays, facial dysmorphisms, and short stature seen in WHS may be due to disruption of WHSC1 gene.